4.5 Review

The Role of Neuroinflammation in Dementias

期刊

出版社

SPRINGER
DOI: 10.1007/s11910-015-0531-7

关键词

Neuroinflammation; Dementia; Alzheimer; Parkinson; Lewy body; Frontotemporal

资金

  1. University of Pisa
  2. PAIM (Pisa, Italy)
  3. Acadia Pharmaceuticals Inc
  4. Amsterdam Molecular Therapeuctics BV
  5. AstraZeneca
  6. BiogeIdec
  7. NeuroNova AB
  8. Eli Lilly and Company
  9. Medtronic Inc
  10. Shire Pharmaceuticals Inc
  11. Synosia Therapeutics AG
  12. GlaxoSmith Kline
  13. UBC Biosciences Inc
  14. Veralis (RD) limited
  15. Genentech Inc
  16. Navidea
  17. Medical Research Council, UK
  18. Alzheimer's Research, UK
  19. Alzheimer's Society, UK
  20. Novo Nordisk
  21. GE Healthcare
  22. Piramal Life Science
  23. MRC [G84/6523] Funding Source: UKRI
  24. Medical Research Council [G84/6523] Funding Source: researchfish

向作者/读者索取更多资源

The molecular mechanism of neuronal loss and synaptic damage in Alzheimer's disease (AD), Parkinson's disease dementia (PDD), frontotemporal dementia (FTD) and Lewy body dementia (LBD) is poorly understood and could differ among different types of neurodegenerative processes. However, the presence of neuroinflammation is a common feature of dementia. In this setting, reactive microgliosis, oxidative damage and mitochondrial dysfunction are associated with the pathogenesis of all types of neurodegenerative dementia. Moreover, an increased body of evidence suggests that microglia may play a central role in AD progression. In this paper, we review the scientific literature on neuroinflammation related to the most common neurodegenerative dementias (AD, PDD, FTD and LBD) focussing on the possible molecular mechanisms and the available clinical evidence. Furthermore, we discuss the neuroimaging techniques that are currently used for the study of neuroinflammation in human brain.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据